. 2022 Jun 9;59(6):2102184. doi: 10.1183/13993003.02184-2021

TABLE 3.

Secondary outcome measures at 26 weeks

	Placebo	Tiotropium	Difference in change adjusted for period (95% CI )	p-value
Exacerbation duration (days)	19.6±14.6^#	21.7±16.9^#	2.4 (−1.5–6.2)	0.49
Time to first exacerbation (days)	104 (80–136)^¶	74 (50–156)^¶	1.00 (0.68–1.46)⁺	0.98
6MWT (m)	522±91	526±79	−0.3 (−8.0–7.3)	0.93
SGRQ domain score
Symptoms	45.5±232.3	46.0±23.1	0.7 (−3.5–4.8)	0.31
Activity	34.7±22.8	33.5±20.9	−0.9 (−3.7–2.0)	0.54
Impacts	23.1±16.5	24.0±16.3	0.5 (−2.1–3.0)	0.72
Total	30.0±17.2	30.5±16.4	0.3 (−2.0–2.6)	0.81
LCQ domain score
Physical	5.21±1.08	5.08±1.19	−0.12 (−0.34–0.10)	0.28
Psychological	5.34±1.47	5.29±1.50	−0.09 (−0.37–0.18)	0.50
Social	5.41±1.36	5.33±1.41	−0.12 (−0.37–0.13)	0.35
Total	16.0±3.8	15.7±3.9	−0.33 (−1.01,0.35)	0.34
CAT score	14.7±6.9	14.6±7.6	−0.17 (−1.47–1.14)	0.80
Peripheral blood cells
White blood cells (×10⁹ mL⁻¹)	8.04±2.53	7.65±1.99	0.97^§ (0.91–1.03)	0.27
Neutrophils (×10⁹ mL⁻¹)	5.03±2.26	4.73±1.72	0.97^§ (0.89–1.05)	0.47
Eosinophils (×10⁹ mL⁻¹)	0.247±0.184	0.311±0.601	1.08^§ (0.94–1.24)	0.30
Sputum cells
Total cells (×10⁹ mL⁻¹)	21.3±28.8	22.9±38.3	0.87^§ (0.78–0.97)	0.016
Neutrophils (×10⁹ mL⁻¹)	21.0±28.7	22.2±37.6	0.90^§ (0.62–1.30)	0.45
Eosinophils (×10⁹ mL⁻¹)	0.15±0.44	0.33±1.38	0.84^ƒ (0.32–2.21)	0.76^¶¶
Eosinophils (×10⁹ mL⁻¹)	0.15±0.44	0.33±1.38	0.83^## (0.35–1.95)	0.76^¶¶
Bronchial epithelial cells (×10⁹ mL⁻¹)	0.13±0.28	0.16±0.27	0.92^ƒ (0.40–2.16)	0.87^¶¶
Bronchial epithelial cells (×10⁹ mL⁻¹)	0.13±0.28	0.16±0.27	1.25^## (0.74–2.10)	0.87^¶¶

Data are presented as mean±sd, unless otherwise stated. 6MWT: 6-min walk test; SGRQ: St George's Respiratory Questionnaire; LCQ: Leicester Cough Questionnaire; CAT: COPD Assessment Test. ^#: sd indicative only, as not all observations independent; ^¶: median (95% CI); ⁺: hazard ratio; ^§: ratio of means; ^ƒ: odds ratio of value being 0; ^##: ratio of means when value >0; ^¶¶: overall p-value.